Janice K. Albrecht

35.1k total citations · 15 hit papers
117 papers, 26.0k citations indexed

About

Janice K. Albrecht is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Janice K. Albrecht has authored 117 papers receiving a total of 26.0k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Hepatology, 72 papers in Epidemiology and 20 papers in Rheumatology. Recurrent topics in Janice K. Albrecht's work include Hepatitis C virus research (85 papers), Liver Disease Diagnosis and Treatment (53 papers) and Hepatitis B Virus Studies (38 papers). Janice K. Albrecht is often cited by papers focused on Hepatitis C virus research (85 papers), Liver Disease Diagnosis and Treatment (53 papers) and Hepatitis B Virus Studies (38 papers). Janice K. Albrecht collaborates with scholars based in United States, France and Germany. Janice K. Albrecht's co-authors include John G. McHutchison, Zachary Goodman, Stuart C. Gordon, Mitchell L. Shiffman, Michael P. Manns, Vinod K. Rustgi, Thierry Poynard, Kenneth Koury, Eugene R. Schiff and Robert Reindollar and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Janice K. Albrecht

113 papers receiving 25.0k citations

Hit Papers

Peginterferon alfa-2b plu... 1989 2026 2001 2013 2001 1998 1998 2011 1989 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    2001 4.8k citations John G. McHutchison, Stuart C. Gordon et al. The Lancet profile →
  2. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
    1998 2.8k citations John G. McHutchison, Stuart C. Gordon et al. New England Journal of Medicine profile →
  3. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
    1998 1.9k citations Thierry Poynard, Patrick Marcellin et al. The Lancet profile →
  4. Boceprevir for Untreated Chronic HCV Genotype 1 Infection
    2011 1.9k citations Fred Poordad, Jonathan McCone et al. New England Journal of Medicine profile →
  5. Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
    1989 1.4k citations Gary L. Davis, Eugene R. Schiff et al. New England Journal of Medicine profile →
  6. Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
    2011 1.2k citations Bruce R. Bacon, Stuart C. Gordon et al. New England Journal of Medicine profile →
  7. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C
    1998 1.1k citations Gary L. Davis, Rafael Esteban et al. New England Journal of Medicine profile →
  8. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
    2009 889 citations John G. McHutchison, Eric Lawitz et al. New England Journal of Medicine profile →
  9. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
    2002 849 citations Thierry Poynard, John G. McHutchison et al. Gastroenterology profile →
  10. Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C
    2002 775 citations John G. McHutchison, Keyur Patel et al. Gastroenterology profile →
  11. A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B
    1990 664 citations Robert P. Perrillo, Karen L. Lindsay et al. New England Journal of Medicine profile →
  12. Early Virologic Response to Treatment With Peginterferon Alfa–2B Plus Ribavirin in Patients With Chronic Hepatitis C
    2003 625 citations Gary L. Davis, John G. McHutchison et al. Hepatology profile →
  13. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C
    2001 548 citations Thierry Poynard, Zachary Goodman et al. Journal of Hepatology profile →
  14. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    2010 515 citations Paul Y. Kwo, Eric Lawitz et al. The Lancet profile →
  15. A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C
    2001 507 citations Karen L. Lindsay, Christian Trépo et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Janice K. Albrecht United States 48 23.6k 21.7k 2.9k 2.5k 1.2k 117 26.0k
Mitchell L. Shiffman United States 75 27.9k 1.2× 27.7k 1.3× 2.8k 0.9× 2.4k 0.9× 2.0k 1.7× 275 34.4k
Patrick Marcellin France 99 34.2k 1.4× 34.3k 1.6× 4.1k 1.4× 2.0k 0.8× 1.4k 1.2× 635 38.8k
Eugene R. Schiff United States 78 22.8k 1.0× 22.5k 1.0× 3.2k 1.1× 1.3k 0.5× 1.3k 1.1× 372 28.9k
Ira M. Jacobson United States 64 17.0k 0.7× 15.7k 0.7× 3.0k 1.0× 1.5k 0.6× 1.0k 0.9× 338 19.9k
Antonio Craxı̀ Italy 73 20.4k 0.9× 20.5k 0.9× 1.9k 0.6× 1.9k 0.8× 1.4k 1.2× 519 27.1k
Geoffrey Dusheiko United Kingdom 60 15.1k 0.6× 14.6k 0.7× 2.4k 0.8× 915 0.4× 1.1k 1.0× 285 18.6k
Stanislas Pol France 71 15.1k 0.6× 14.2k 0.7× 3.1k 1.1× 1.2k 0.5× 925 0.8× 484 18.9k
Daniel Dhumeaux France 63 13.8k 0.6× 12.1k 0.6× 1.3k 0.4× 1.3k 0.5× 1.1k 1.0× 283 17.9k
Vinod K. Rustgi United States 35 11.9k 0.5× 10.7k 0.5× 1.6k 0.5× 1.2k 0.5× 782 0.7× 173 13.8k
A. Albertí Italy 62 12.5k 0.5× 12.7k 0.6× 1.1k 0.4× 931 0.4× 880 0.8× 400 15.7k

Countries citing papers authored by Janice K. Albrecht

Since Specialization
Citations

This map shows the geographic impact of Janice K. Albrecht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janice K. Albrecht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janice K. Albrecht more than expected).

Fields of papers citing papers by Janice K. Albrecht

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Janice K. Albrecht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janice K. Albrecht. The network helps show where Janice K. Albrecht may publish in the future.

Co-authorship network of co-authors of Janice K. Albrecht

This figure shows the co-authorship network connecting the top 25 collaborators of Janice K. Albrecht. A scholar is included among the top collaborators of Janice K. Albrecht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janice K. Albrecht. Janice K. Albrecht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Niedermayer, W., et al.. (2015). Clinical Multicenter Study of Hemoflow F6 in Comparison with Different Standard Dialyzers. Contributions to nephrology. 74. 22–33.
2.
Gordon, Stuart C., Eric M. Yoshida, Eric Lawitz, et al.. (2013). Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa‐2b/ribavirin. Alimentary Pharmacology & Therapeutics. 38(1). 16–27. 17 indexed citations
3.
Barnard, Richard J. O., John A. Howe, Robert A. Ogert, et al.. (2013). Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 444(1-2). 329–336. 54 indexed citations
4.
Clark, Paul J., Alexander Thompson, Stuart C. Gordon, et al.. (2013). Predictors of consent to pharmacogenomics testing in the IDEAL study. Pharmacogenetics and Genomics. 23(11). 619–623. 2 indexed citations
5.
Sulkowski, Mark S., Fred Poordad, M.P. Manns, et al.. (2012). Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology. 57(3). 974–984. 52 indexed citations
6.
Jacobson, Ira M., Patrick Marcellin, Stefan Zeuzem, et al.. (2012). Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology. 56(2). 567–575. 47 indexed citations
7.
Flamm, Steven L., Eric Lawitz, Ira M. Jacobson, et al.. (2012). Boceprevir With Peginterferon Alfa-2a–Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection. Clinical Gastroenterology and Hepatology. 11(1). 81–87.e4. 49 indexed citations
8.
Clark, Paul J., Alexander Thompson, Stuart C. Gordon, et al.. (2011). PREDICTORS OF CONSENT TO PHARMACOGENOMICS TESTING IN THE IDEAL STUDY. Hepatology. 54.
9.
10.
Thompson, Alexander, Paul J. Clark, David M. Vock, et al.. (2011). PREDICTING PEGINTERFERON-alpha AND RIBAVIRIN TREATMENT RESPONSE IN GENOTYPE 1 HCV PATIENTS - SIMPLE NOMOGRAMS TO SUPPORT CLINICIANS. Hepatology. 54. 95–8. 1 indexed citations
11.
Thompson, Alexander, Paul J. Clark, Hans L. Tillmann, et al.. (2011). Il28B C/c Genotype Is Predictive of >= 1 Log10 Iu/ml Reduction in Plasma Hcv Rna After 4 Weeks of Peginterferon (Pegifn) and Ribavirin (Rbv) Therapy: Implications for the Use of the Lead-In Strategy for Direct-Acting Antiviral-Based Treatment Regimens. Hepatology. 54. 3 indexed citations
12.
Bacon, Bruce R., Stuart C. Gordon, Eric Lawitz, et al.. (2011). Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection. New England Journal of Medicine. 364(13). 1207–1217. 1229 indexed citations breakdown →
13.
Kwo, Paul Y., Eric Lawitz, Jonathan McCone, et al.. (2010). Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. The Lancet. 376(9742). 705–716. 515 indexed citations breakdown →
14.
Sulkowski, Mark, Mitchell L. Shiffman, Nezam H. Afdhal, et al.. (2010). Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate. Gastroenterology. 139(5). 1602–1611.e1. 82 indexed citations
15.
Zeuzem, Stefan, Marı́a Buti, Peter Ferenci, et al.. (2005). Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. Journal of Hepatology. 44(1). 97–103. 334 indexed citations
16.
McHutchison, John G., Thierry Poynard, Stephen Pianko, et al.. (2000). The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology. 119(5). 1317–1323. 155 indexed citations
17.
Gordon, Stuart C., Jane Fang, Ann L. Silverman, John G. McHutchison, & Janice K. Albrecht. (2000). The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology. 32(2). 400–404. 59 indexed citations
18.
Poynard, Thierry, John G. McHutchison, Zachary Goodman, Mei-Hsiu Ling, & Janice K. Albrecht. (2000). Is an “à la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?. Hepatology. 31(1). 211–218. 297 indexed citations
19.
Davis, Gary L., Rafael Esteban, Vinod K. Rustgi, et al.. (1998). Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C. New England Journal of Medicine. 339(21). 1493–1499. 1070 indexed citations breakdown →
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mitchell L. Shiffman Breakdown of academic impact, for papers by Patrick Marcellin Breakdown of academic impact, for papers by Eugene R. Schiff Breakdown of academic impact, for papers by Ira M. Jacobson Breakdown of academic impact, for papers by Antonio Craxı̀ Breakdown of academic impact, for papers by Geoffrey Dusheiko Breakdown of academic impact, for papers by Stanislas Pol Breakdown of academic impact, for papers by Daniel Dhumeaux Breakdown of academic impact, for papers by Vinod K. Rustgi Breakdown of academic impact, for papers by A. Albertí
Rankless by CCL
2026